Heron Therapeutics (HRTX) Tax Provisions (2014 - 2015)
Heron Therapeutics' (HRTX) quarterly Tax Provisions came in at $113.7 million in Q4 2015, up 94664.17% on a YoY basis from N/an in Q4 2014, and up 94664.17% quarter-over-quarter from $120000.0 in Q4 2014.
Powered by 
Analysis
Heron Therapeutics (HRTX) Tax Provisions (2014 - 2015) Analysis & Trends
Heron Therapeutics (HRTX) has reported Tax Provisions for 2 consecutive years, with $113.7 million the latest figure, recorded in Q4 2015.
- For the quarter ending Q4 2015, Tax Provisions rose 94664.17% year-over-year to $113.7 million; the trailing twelve-month figure through Dec 2015 stood at $113.7 million (up 94664.17% YoY), and the FY2015 full-year result was $113.7 million, up 537.96% from the prior year.
- Tax Provisions climbed to $113.7 million in Q4 2015 per HRTX's latest filing, from $120000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $113.7 million in Q4 2015 and bottomed at $120000.0 in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Heron Therapeutics | 64.55 Mn | 21.89 Mn | 26.09 Mn | - |